Strategic Acquisition Impact Merck's recent acquisition of Acceleron Pharma for $11.5 billion presents a significant cross-selling opportunity to promote combined product portfolios and expand market reach.
Innovative Drug Launches Acceleron Pharma's successful launch of Reblozyl for MDS treatment signifies a growing market presence, creating an opportunity to upsell and offer complementary products to existing and potential clients.
Partnership Development Collaboration with Merck through a definitive merger agreement and subsequent partnership opens doors for joint sales strategies, leveraging each other's strengths to tap into new customer segments.
Competitive Landscape Analysis Exploring the failed acquisition attempt by New York Pharma and current competitive landscape with companies like bluebird bio and Vertex Pharmaceuticals can provide insights to position products effectively and win market share.
Financial Strength for Growth With Acceleron Pharma's $493 million funding and estimated revenue between $50-100 million, there is room for investment in sales teams, marketing campaigns, and product development to drive revenue growth and market expansion.
587
$50M$100M
6.1K$1B
966$100M$1B
5K$100M$1B
3.6K$100M$1B
1.5K$1B
334$50M$100M
1.5K$100M$1B
585$50M$100MAcceleron Pharma uses 8 technology products and services including SiteCatalyst, GitHub, SAP, and more. Explore Acceleron Pharma's tech stack below.
| Acceleron Pharma Email Formats | Percentage |
| FLast@acceleronpharma.com | 92% |
| First.Last@acceleronpharma.com | 5% |
| Last@acceleronpharma.com | 2% |
| FMiddleLast@acceleronpharma.com | 1% |
Biotechnology ResearchMassachusetts, United States201-500 Employees
Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com
Company Overview
Media & News
Funding & FinancialsAcceleron Pharma has raised a total of $493M of funding over 15 rounds. Their latest funding round was raised on Jun 30, 2020 in the amount of $493M.
Acceleron Pharma's revenue is in the range of $50M$100M
Funding & FinancialsAcceleron Pharma has raised a total of $493M of funding over 15 rounds. Their latest funding round was raised on Jun 30, 2020 in the amount of $493M.
Acceleron Pharma's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com